Dominari (NASDAQ:DOMH) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Dominari (NASDAQ:DOMH) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Dominari in a research note on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Dominari Stock Performance

Shares of NASDAQ DOMH opened at $2.71 on Friday. The company has a market capitalization of $65.70 million, a PE ratio of -0.50 and a beta of 0.87. The company’s fifty day moving average price is $2.88 and its 200 day moving average price is $3.12. Dominari has a 1 year low of $2.19 and a 1 year high of $8.40.

Dominari (NASDAQ:DOMH) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.13. The company had revenue of $16.79 million during the quarter, compared to analysts’ expectations of $16.79 million. Dominari had a negative net margin of 51.61% and a negative return on equity of 235.37%.

Hedge Funds Weigh In On Dominari

A number of large investors have recently added to or reduced their stakes in DOMH. Renaissance Technologies LLC lifted its holdings in Dominari by 59.1% during the first quarter. Renaissance Technologies LLC now owns 132,362 shares of the company’s stock valued at $430,000 after purchasing an additional 49,162 shares in the last quarter. PFG Investments LLC grew its position in shares of Dominari by 36.3% in the first quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock valued at $47,000 after purchasing an additional 3,855 shares during the period. Creek Drive Management Group LLC purchased a new stake in shares of Dominari during the fourth quarter worth about $1,861,000. NewEdge Advisors LLC purchased a new stake in shares of Dominari during the fourth quarter worth about $50,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of Dominari during the fourth quarter worth about $120,000. 42.48% of the stock is currently owned by institutional investors and hedge funds.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.